0000899243-20-000395.txt : 20200103 0000899243-20-000395.hdr.sgml : 20200103 20200103204118 ACCESSION NUMBER: 0000899243-20-000395 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200102 FILED AS OF DATE: 20200103 DATE AS OF CHANGE: 20200103 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ADELMAN DANIEL C MD CENTRAL INDEX KEY: 0001222037 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37519 FILM NUMBER: 20507836 MAIL ADDRESS: STREET 1: 23 WOODLEAF AVENUE CITY: REDWOOD CITY STATE: CA ZIP: 94061 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc. CENTRAL INDEX KEY: 0001631650 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452748244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 BUSINESS PHONE: (650) 614-5220 MAIL ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005-1884 FORMER COMPANY: FORMER CONFORMED NAME: Allergen Research Corp DATE OF NAME CHANGE: 20150123 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-01-02 0 0001631650 Aimmune Therapeutics, Inc. AIMT 0001222037 ADELMAN DANIEL C MD AIMMUNE THERAPEUTICS, INC. 8000 MARINA BOULEVARD, SUITE 300 BRISBANE CA 94005-1884 0 1 0 0 Chief Medical Officer Common Stock, $0.0001 par value 2020-01-02 4 M 0 20000 19.63 A 41250 D Common Stock, $0.0001 par value 2020-01-02 4 S 0 20000 35.0019 D 21250 D Stock Option (right to buy) 19.63 2020-01-02 4 M 0 20000 0.00 D 2027-02-24 Common Stock 20000 70000 D The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Includes 11,875 restricted stock units ("RSUs") which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2019, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Includes 9,375 RSUs which will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from March 1, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. Represents the weighted average sale price for the entire number of shares sold. The sale prices range from $34.99 to $35.04 per share. Information on the actual numbers of shares sold at each sale price can be obtain from the Issuer upon request. The shares subject to the option will vest and become exercisable as to one-forty-eighth (1/48th) of the total number of shares subject to the option in successive, equal monthly installments measured from February 24, 2017, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date. /s/ Douglas T. Sheehy, as Attorney in Fact for Daniel C. Adelman 2020-01-03